Evidence map›Paper›PMID 24126796›Full record

ArticleProstate cancer and prostatic diseases2014

Predicting utility scores for prostate cancer: mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS).

K E Bremner, N Mitsakakis, L Wilson, M D Krahn

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

K E Bremner1] Toronto General Hospital, Clinical Decision Making and Health Care, University Health Network, Toronto, Ontario, Canada [2] Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, Ontario, Canada.
N MitsakakisToronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, Ontario, Canada.
L WilsonFaculty of Pharmacy, University of California San Francisco, San Francisco, CA, USA.
M D Krahn1] Toronto General Hospital, Clinical Decision Making and Health Care, University Health Network, Toronto, Ontario, Canada [2] Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, Ontario, Canada [3] Department of Medicine, Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada [4] Department of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Toronto Public Health · CAToronto General Hospital · CAUniversity of California, San Francisco · US

Funding

Canadian Institutes of Health Research 006169Canadian Institutes of Health Research 53114
6 · The paper itself

Abstract

backgroundThe Prostate Cancer Index (PCI) is a health profile instrument that measures health-related quality of life with six subscales: urinary, sexual, and bowel function and bother. The Patient-Oriented Prostate Utility Scale (PORPUS-U) measures utility (0=dead and 1=full health). Utility is a preference-based approach to measure health-related quality of life, required for decision analyses and cost-effectiveness analyses. We developed a function to estimate PORPUS-U utilities from PCI scores.

methodsThe development data set included 676 community-dwelling prostate cancer (PC) survivors who completed the PCI and PORPUS-U by mail. We fit three linear regression models: one used original PORPUS-U scores and two used log-transformed PORPUS-U scores, one with a hierarchy constraint and one without. The model selection was performed using stepwise selection and fivefold cross validation. The validation data included 248 PC outpatients with three assessments on the PCI and PORPUS-U. Scores were retransformed for validation, with Duan's smearing estimator applied to correct potential bias. The predictive ability of the models was assessed with R(2), root mean square error (RMSE) and by comparing predicted and observed utilities.

resultsThe best-fitting model used the log-transformed PORPUS-U with no hierarchy constraint. The R(2) was 0.72. The RMSE ranged from 0.040 to 0.061 for the three validation data sets. Differences between predicted and observed utilities ranged from 0.000 to 0.006 but predicted utilities overestimated the lowest 5% of observed PORPUS-U scores and underestimated the highest observed scores.

conclusionsOur algorithm can calculate PORPUS-U utility scores from PCI scores, thus supplementing descriptive quality of life measures with utility scores in PC patients. Utilities derived from mapping algorithms are useful for assigning utility to groups of patients but are less accurate at predicting utility of individual patients. We are exploring statistical methods to improve the mapping of utilities from descriptive instruments.

Indexed as

Models, StatisticalProstatic NeoplasmsQuality of LifeAdultAgedAged, 80 and overCohort StudiesComorbidityHumansMaleMiddle AgedNeoplasm MetastasisRisk FactorsSeverity of Illness Index

Identifiers

PMID24126796
OpenAlexW2054119554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.